SuperGen Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Apr 28 Calls Today's Calls

Call Details SuperGen Earnings Conference Call (Q1 2008) Mon, Apr 28, 2008, 4:30 pm Eastern Listen to the archived event audio About SuperGen (NasdaqGM:SUPG) SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. It offers Orathecin, a Phase III clinical trail product for the treatment of solid tumors; Mitozytrex for the treatment of solid tumors, which is in approval stage; Partaject busulfan, a Phase I/II clinical trail product for neoplastic meningitis/bone marrow transplant; Partaject Orathecin, a pre-clinical stage product for the treatment of solid tumors; CZ 112, a Phase I clinical trail product for the treatment of solid tumors; Cremophor-free paclitaxel, a pre-clinical stage product for the treatment of solid tumors; Avicine, a therapeutic vaccine for the treatment of cancer, which is in Phase II trails; VEGF, a pre-clinical stage product for the treatment of anti-angiogenesis; PZG, a Phase II clinical trail product for the treatment of type II diabetes; and AM454 is phosphocholine derivative is in pre-clinical stage for obesity/diabetes. The company sells its products to clinics, hospitals, and hospital buying groups, as well as to drug distributors and wholesalers in the United States and Europe. SuperGen was founded in 1991 and is based in Dublin, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings